AllazoHealth uses artificial intelligence to make a positive impact on individual patient behavior.
AllazoHealth’s AI engine:
- Predicts patients who are at risk for non-adherence, and who are likely to respond to engagement
- Selects the channel, content and timing to deliver the most effective engagement, personalized for each patient
- Optimizes the engagement over time to deliver continual improvement
WHO WE HELP
AllazoHealth partners with brands to improve patient adherence. We help brands achieve impact by optimizing personalized engagement. The result: better patient outcomes and increased brand performance.
AllazoHealth uses artificial intelligence to make a positive impact on patient adherence. We work with pharmacies to improve clinical outcomes and increase reimbursement from pay-for-performance contracts such as DIR.
AllazoHealth uses artificial intelligence to improve individual patient adherence. We help payers and PBMs increase effectiveness of patient engagement programs that focus on quality ratings.
Improving the effectiveness of adherence interventions by
5.45x
We worked alongside Blue Cross Blue Shield of North Carolina and their call center vendor to launch one of our biggest programs, working to improve adherence rates across their population of 104,392 Medicare Advantage Part D (MAPD) patients. We found that AllazoHealth targeted interventions accounted for 5.45 times the uplift in adherence compared to traditionally targeted interventions.
Bridging gaps in care with artificial intelligence
As US payers and providers struggle with a fragmented healthcare system, patients with chronic conditions continue to experience gaps in their care. An AARP survey…
Senior medication adherence: the growing problem
By the year 2030 the entire Baby Boomer generation will be age 65 or older. This growing number of senior Boomers will challenge the health…
Improving diabetes adherence: pharmacies, Medicare Advantage Plans and AI
In the field of chronic diseases, Type 2 diabetes ranks high when it comes to the challenges of therapy initiation and non-adherence. Diabetes accounts for…